SubCyclo Clinical Data - SubLiminal Laser Therapy

> A new treatment for advanced and end-stage glaucoma

Primary angle glaucoma, primary angle closure glaucoma, pseudo-exfoliation, neovascular glaucoma, glaucoma associated with steroid uses, uveitis and after keratoplasty surgery⁽¹⁾

> A very efficient non thermal procedure leading to a reduction in the medication regimen

Significant and persistent reduction in IOP at 9 months⁽¹⁾

30 % decrease from baseline and less than 21 mmHg

Mean number of medication⁽¹⁾

Before treatment: 3,4 ± 1,7
After treatment: 2,9 ± 1,6

> SubCyclo^® preserves the structures of the ciliary body (no destructive effects) and improves the uveoscleral drainage

After treatment:

No anatomical damage or visible lesion have been observed by ultrasound biomicroscopy⁽¹⁾
UBM shows a thin space between sclera and ciliary body which may correspond to the presence of suprachoroidal fluid[mfn](1)[/mfn]

Image courtesy of Dr. Nassima Benhatchi

> SubCyclo^® avoids the side effects of the thermal cyclophotocoagulation procedure

No serious side effects such as intraocular inflammation after treatment⁽¹⁾
No severe complications such as phthisis bulbi, persistent hypotony, or cystoid macular edema⁽¹⁾

> A repeatable treatment⁽¹⁾

> A safe treatment potentially allowing for earlier laser interventions

SubCyclo - A new perspective in Glaucoma Treatment

Yves Lachkar, MD

Nassima Benhatchi, MD

Subcyclo laser procedure results in patients with glaucoma
Transscleral cyclophotocoagulation uses a continuous diode laser and it has been a treatment option in advanced glaucoma cases with suboptimal IOP control

By Romanian Society of Ophthalmology

READ

Significant Improvements for IOP Reduction Seen in SubCyclo
As a leading cause of irreversible blindness worldwide, glaucoma affects around 60.5 million people globally. Significant changes in diagnostic criteria, new therapies, and new tools for glaucoma management techniques have benefited individual patients.

By Robert Noecker, MD

READ

(1) – Efficacy, tolerability, side effects, anatomical effects (UBM) of SubCyclo^® subthreshold cyclophotocoagulation. 9-month study (43 eyes / 34 patients) presented at the French Society of Ophthalmology 2017 (SFO). Dr. Yves Lachkar and Dr. Nassima Benhatchi – Glaucoma Institute, Saint Joseph Hospital, Paris (France). Data on file

MORE INFORMATION:

Introduction to SubCyclo

Treatment Guidelines